Last reviewed · How we verify
Placebo - Piroxicam
Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and decrease inflammation and pain.
Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and decrease inflammation and pain. Used for Rheumatoid arthritis, Osteoarthritis, Acute musculoskeletal pain and inflammation.
At a glance
| Generic name | Placebo - Piroxicam |
|---|---|
| Sponsor | The University of Hong Kong |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
Piroxicam non-selectively inhibits both COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. By blocking prostaglandin synthesis, piroxicam reduces inflammatory responses and provides analgesic and antipyretic effects. It is a long-acting NSAID with a prolonged half-life, allowing for once-daily dosing.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Acute musculoskeletal pain and inflammation
Common side effects
- Gastrointestinal upset (dyspepsia, nausea)
- Abdominal pain
- Headache
- Dizziness
- Rash
- Gastrointestinal bleeding
Key clinical trials
- Rct Assessing Pregnancy - Piroxicam for Ec With Levonorgestrel (PHASE3)
- Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception (PHASE3)
- Enantyum® IV Versus Piroxen® IM in Emergency Pain Management (PHASE3)
- Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception (PHASE2, PHASE3)
- Oral NSAI Versus Paracetamol or Placebo as a Second Line Treatment for Renal Colics (PHASE3)
- Oral NSAI Versus Acetaminophen or Placebo as a Discharge Treatment of Non Complicated Renal Colics (PHASE2)
- Efficacy of Piroxicam as a Perioperative Analgesic for Patients Undergoing Fixation of Maxillofacial Fractures (EARLY_PHASE1)
- Piroxicam Premedication for Postendodontic Pain in Non-vital Mandibular Molars (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo - Piroxicam CI brief — competitive landscape report
- Placebo - Piroxicam updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI